| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| MicroRNAs | 17 | 2024 | 2887 | 3.020 |
Why?
|
| Laryngeal Neoplasms | 6 | 2016 | 529 | 2.270 |
Why?
|
| Prostatic Neoplasms | 19 | 2020 | 5866 | 1.430 |
Why?
|
| Neoplastic Stem Cells | 6 | 2016 | 1456 | 1.250 |
Why?
|
| Biomarkers, Tumor | 11 | 2020 | 10708 | 1.020 |
Why?
|
| ATP-Binding Cassette Transporters | 2 | 2015 | 317 | 0.880 |
Why?
|
| Chordoma | 3 | 2013 | 170 | 0.800 |
Why?
|
| Carcinoma, Squamous Cell | 5 | 2015 | 5593 | 0.800 |
Why?
|
| SOXB1 Transcription Factors | 3 | 2015 | 119 | 0.710 |
Why?
|
| Alternative Splicing | 2 | 2019 | 611 | 0.710 |
Why?
|
| Mutation, Missense | 3 | 2015 | 1192 | 0.700 |
Why?
|
| Gene Expression Regulation, Neoplastic | 15 | 2017 | 9042 | 0.690 |
Why?
|
| rab3 GTP-Binding Proteins | 1 | 2019 | 18 | 0.660 |
Why?
|
| Gene Expression Profiling | 11 | 2024 | 5149 | 0.650 |
Why?
|
| Optic Atrophy | 1 | 2019 | 51 | 0.630 |
Why?
|
| Abnormalities, Multiple | 4 | 2019 | 1023 | 0.590 |
Why?
|
| Skin Abnormalities | 2 | 2014 | 32 | 0.580 |
Why?
|
| Mutation | 6 | 2019 | 15912 | 0.570 |
Why?
|
| Microcephaly | 3 | 2019 | 333 | 0.560 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2020 | 10400 | 0.560 |
Why?
|
| Transfection | 6 | 2015 | 3117 | 0.560 |
Why?
|
| Cataract | 1 | 2019 | 236 | 0.540 |
Why?
|
| CHARGE Syndrome | 1 | 2015 | 9 | 0.520 |
Why?
|
| Receptors, Fibroblast Growth Factor | 4 | 2004 | 153 | 0.520 |
Why?
|
| Centrioles | 1 | 2015 | 15 | 0.510 |
Why?
|
| RNA Splice Sites | 1 | 2015 | 117 | 0.500 |
Why?
|
| Usher Syndromes | 1 | 2015 | 9 | 0.500 |
Why?
|
| White Coat Hypertension | 1 | 2015 | 10 | 0.500 |
Why?
|
| Hypogonadism | 1 | 2019 | 278 | 0.500 |
Why?
|
| alpha-Crystallin B Chain | 1 | 2014 | 4 | 0.480 |
Why?
|
| Saliva | 1 | 2015 | 238 | 0.480 |
Why?
|
| Dwarfism | 1 | 2015 | 110 | 0.470 |
Why?
|
| Ephrin-B1 | 1 | 2013 | 11 | 0.450 |
Why?
|
| Foot Deformities | 1 | 2013 | 4 | 0.450 |
Why?
|
| Cornea | 1 | 2019 | 681 | 0.450 |
Why?
|
| Tongue Neoplasms | 1 | 2015 | 253 | 0.450 |
Why?
|
| Tyrosinemias | 1 | 2013 | 24 | 0.440 |
Why?
|
| Prostate | 3 | 2017 | 1089 | 0.430 |
Why?
|
| DNA Helicases | 1 | 2015 | 450 | 0.420 |
Why?
|
| ZAP-70 Protein-Tyrosine Kinase | 1 | 2012 | 107 | 0.410 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 7 | 2018 | 2471 | 0.410 |
Why?
|
| Up-Regulation | 6 | 2015 | 2422 | 0.410 |
Why?
|
| Cochlea | 1 | 2013 | 118 | 0.400 |
Why?
|
| Severe Combined Immunodeficiency | 1 | 2012 | 111 | 0.400 |
Why?
|
| Limb Deformities, Congenital | 1 | 2013 | 116 | 0.400 |
Why?
|
| Down-Regulation | 6 | 2015 | 2090 | 0.400 |
Why?
|
| Male | 39 | 2024 | 128315 | 0.400 |
Why?
|
| Real-Time Polymerase Chain Reaction | 5 | 2020 | 1199 | 0.390 |
Why?
|
| Craniofacial Abnormalities | 1 | 2013 | 250 | 0.380 |
Why?
|
| Intellectual Disability | 1 | 2019 | 1065 | 0.380 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2013 | 154 | 0.370 |
Why?
|
| Neutropenia | 1 | 2014 | 1006 | 0.340 |
Why?
|
| Cell Proliferation | 5 | 2015 | 7238 | 0.340 |
Why?
|
| Skull Base Neoplasms | 1 | 2013 | 339 | 0.330 |
Why?
|
| Case-Control Studies | 6 | 2024 | 6224 | 0.330 |
Why?
|
| Humans | 48 | 2024 | 270740 | 0.320 |
Why?
|
| Pedigree | 4 | 2019 | 2042 | 0.310 |
Why?
|
| Prenatal Diagnosis | 1 | 2012 | 610 | 0.310 |
Why?
|
| Lymphocytes | 1 | 2013 | 1275 | 0.300 |
Why?
|
| Sequence Analysis, DNA | 1 | 2015 | 2573 | 0.290 |
Why?
|
| Tumor Cells, Cultured | 6 | 2016 | 5759 | 0.280 |
Why?
|
| Proteins | 1 | 2015 | 2043 | 0.280 |
Why?
|
| Fibroblast Growth Factor 2 | 2 | 2004 | 241 | 0.270 |
Why?
|
| Turkey | 2 | 2019 | 66 | 0.270 |
Why?
|
| Middle Aged | 16 | 2024 | 90352 | 0.260 |
Why?
|
| Genes, Dominant | 2 | 2004 | 356 | 0.260 |
Why?
|
| AC133 Antigen | 2 | 2016 | 107 | 0.250 |
Why?
|
| cdc25 Phosphatases | 1 | 2005 | 101 | 0.240 |
Why?
|
| Prostatectomy | 3 | 2020 | 1003 | 0.240 |
Why?
|
| Female | 24 | 2024 | 148940 | 0.240 |
Why?
|
| Phenotype | 4 | 2019 | 6509 | 0.240 |
Why?
|
| Electroconvulsive Therapy | 1 | 2024 | 63 | 0.220 |
Why?
|
| Lymph Nodes | 1 | 2014 | 3077 | 0.220 |
Why?
|
| Neoplasm Proteins | 2 | 2014 | 3345 | 0.220 |
Why?
|
| DNA-Binding Proteins | 2 | 2015 | 5002 | 0.210 |
Why?
|
| Cell Cycle Proteins | 2 | 2015 | 2115 | 0.200 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2015 | 3597 | 0.200 |
Why?
|
| Genetic Therapy | 2 | 2014 | 1716 | 0.200 |
Why?
|
| ROC Curve | 2 | 2015 | 1248 | 0.190 |
Why?
|
| Schizophrenia | 1 | 2024 | 317 | 0.190 |
Why?
|
| Adenoviridae | 2 | 2004 | 1497 | 0.190 |
Why?
|
| Tissue Kallikreins | 1 | 2020 | 9 | 0.190 |
Why?
|
| Prognosis | 5 | 2018 | 22505 | 0.180 |
Why?
|
| Adult | 11 | 2024 | 82040 | 0.180 |
Why?
|
| Cell Line, Tumor | 7 | 2015 | 14849 | 0.160 |
Why?
|
| Head and Neck Neoplasms | 1 | 2014 | 4147 | 0.160 |
Why?
|
| Bone Neoplasms | 1 | 2011 | 2665 | 0.160 |
Why?
|
| INDEL Mutation | 1 | 2019 | 114 | 0.160 |
Why?
|
| Blotting, Western | 3 | 2015 | 3584 | 0.150 |
Why?
|
| Infant | 7 | 2016 | 13999 | 0.150 |
Why?
|
| Aged | 8 | 2015 | 73333 | 0.140 |
Why?
|
| Apoptosis | 5 | 2015 | 7757 | 0.140 |
Why?
|
| Siblings | 1 | 2019 | 319 | 0.140 |
Why?
|
| Receptors, Oxytocin | 1 | 2016 | 22 | 0.140 |
Why?
|
| Child | 7 | 2019 | 30559 | 0.140 |
Why?
|
| Child, Preschool | 6 | 2016 | 17061 | 0.140 |
Why?
|
| Homozygote | 1 | 2019 | 772 | 0.140 |
Why?
|
| Mannose-Binding Protein-Associated Serine Proteases | 1 | 2015 | 1 | 0.130 |
Why?
|
| RNA, Neoplasm | 1 | 2018 | 805 | 0.130 |
Why?
|
| Phorbols | 1 | 2015 | 11 | 0.130 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2015 | 104 | 0.130 |
Why?
|
| Mendelian Randomization Analysis | 1 | 2015 | 105 | 0.120 |
Why?
|
| Hep G2 Cells | 1 | 2015 | 146 | 0.120 |
Why?
|
| Spheroids, Cellular | 1 | 2015 | 220 | 0.120 |
Why?
|
| Disease Progression | 3 | 2015 | 6867 | 0.120 |
Why?
|
| G1 Phase | 1 | 2015 | 305 | 0.120 |
Why?
|
| Retinitis Pigmentosa | 1 | 2015 | 85 | 0.120 |
Why?
|
| Octamer Transcription Factor-3 | 1 | 2014 | 105 | 0.120 |
Why?
|
| Phosphotransferases | 1 | 2014 | 82 | 0.120 |
Why?
|
| Preoperative Period | 1 | 2015 | 346 | 0.120 |
Why?
|
| Microarray Analysis | 1 | 2015 | 396 | 0.110 |
Why?
|
| RNA, Transfer | 1 | 2014 | 88 | 0.110 |
Why?
|
| Cutis Laxa | 1 | 2013 | 10 | 0.110 |
Why?
|
| Prostatic Hyperplasia | 1 | 2014 | 201 | 0.110 |
Why?
|
| Central Nervous System Diseases | 1 | 2014 | 134 | 0.110 |
Why?
|
| Hearing Loss | 1 | 2015 | 172 | 0.110 |
Why?
|
| Postoperative Period | 1 | 2015 | 666 | 0.110 |
Why?
|
| Ichthyosis | 1 | 2012 | 19 | 0.110 |
Why?
|
| MCF-7 Cells | 1 | 2014 | 547 | 0.110 |
Why?
|
| Hyaluronan Receptors | 1 | 2014 | 248 | 0.110 |
Why?
|
| Hashimoto Disease | 1 | 2013 | 24 | 0.110 |
Why?
|
| Cytoskeletal Proteins | 1 | 2015 | 522 | 0.100 |
Why?
|
| Metal Nanoparticles | 1 | 2014 | 161 | 0.100 |
Why?
|
| Gold | 1 | 2014 | 267 | 0.100 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2014 | 277 | 0.100 |
Why?
|
| Area Under Curve | 1 | 2014 | 729 | 0.100 |
Why?
|
| Karyotype | 1 | 2013 | 237 | 0.100 |
Why?
|
| Dermatitis | 1 | 2012 | 61 | 0.100 |
Why?
|
| Hamartoma | 1 | 2013 | 90 | 0.100 |
Why?
|
| CDC2 Protein Kinase | 2 | 2004 | 188 | 0.100 |
Why?
|
| RNA Interference | 1 | 2016 | 1388 | 0.100 |
Why?
|
| Flow Cytometry | 2 | 2013 | 3045 | 0.100 |
Why?
|
| HeLa Cells | 1 | 2015 | 1685 | 0.100 |
Why?
|
| Cell Separation | 1 | 2014 | 609 | 0.100 |
Why?
|
| Immunoglobulin E | 1 | 2012 | 182 | 0.100 |
Why?
|
| Fibroblasts | 2 | 2015 | 1654 | 0.100 |
Why?
|
| Heterozygote | 1 | 2015 | 1056 | 0.100 |
Why?
|
| Exons | 1 | 2015 | 1383 | 0.100 |
Why?
|
| Cell Division | 4 | 2004 | 2657 | 0.100 |
Why?
|
| Gene Regulatory Networks | 1 | 2015 | 680 | 0.100 |
Why?
|
| Cell Survival | 4 | 2012 | 3063 | 0.090 |
Why?
|
| Lymphocyte Count | 1 | 2012 | 485 | 0.090 |
Why?
|
| Autism Spectrum Disorder | 1 | 2016 | 377 | 0.090 |
Why?
|
| Nervous System Diseases | 1 | 2015 | 517 | 0.090 |
Why?
|
| Cell Differentiation | 4 | 2011 | 4116 | 0.090 |
Why?
|
| Promoter Regions, Genetic | 2 | 2016 | 3216 | 0.090 |
Why?
|
| Oncogenes | 1 | 2014 | 699 | 0.090 |
Why?
|
| Amino Acid Substitution | 1 | 2012 | 657 | 0.090 |
Why?
|
| Spinal Cord Neoplasms | 1 | 2012 | 155 | 0.090 |
Why?
|
| Cluster Analysis | 1 | 2013 | 1075 | 0.090 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2014 | 401 | 0.090 |
Why?
|
| Stem Cells | 2 | 2007 | 1216 | 0.090 |
Why?
|
| Prostate-Specific Antigen | 1 | 2014 | 1029 | 0.090 |
Why?
|
| Biopsy, Needle | 1 | 2014 | 1379 | 0.090 |
Why?
|
| Cell Movement | 2 | 2015 | 2472 | 0.090 |
Why?
|
| Glycoproteins | 1 | 2014 | 779 | 0.090 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2014 | 1126 | 0.090 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2015 | 1002 | 0.090 |
Why?
|
| Exome | 1 | 2015 | 1248 | 0.090 |
Why?
|
| Skin | 1 | 2015 | 1271 | 0.090 |
Why?
|
| RNA, Messenger | 2 | 2013 | 6390 | 0.080 |
Why?
|
| Nanoparticles | 1 | 2014 | 585 | 0.080 |
Why?
|
| DNA Mutational Analysis | 1 | 2015 | 2357 | 0.080 |
Why?
|
| Rare Diseases | 1 | 2013 | 360 | 0.080 |
Why?
|
| Amino Acid Sequence | 1 | 2015 | 4567 | 0.080 |
Why?
|
| Antineoplastic Agents | 2 | 2011 | 14617 | 0.080 |
Why?
|
| Etoposide | 1 | 2011 | 907 | 0.080 |
Why?
|
| Pilot Projects | 1 | 2015 | 2828 | 0.080 |
Why?
|
| Base Sequence | 1 | 2015 | 5437 | 0.080 |
Why?
|
| Antigens, CD | 1 | 2014 | 1418 | 0.080 |
Why?
|
| Polymerase Chain Reaction | 1 | 2015 | 3476 | 0.080 |
Why?
|
| Cohort Studies | 2 | 2018 | 9470 | 0.080 |
Why?
|
| Family | 1 | 2012 | 783 | 0.080 |
Why?
|
| Cell Lineage | 1 | 2011 | 701 | 0.080 |
Why?
|
| Molecular Sequence Data | 1 | 2015 | 6685 | 0.080 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2012 | 714 | 0.080 |
Why?
|
| Chromosome Aberrations | 1 | 2015 | 2035 | 0.080 |
Why?
|
| Peptides | 1 | 2014 | 1504 | 0.080 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2011 | 742 | 0.070 |
Why?
|
| Methotrexate | 1 | 2011 | 1025 | 0.070 |
Why?
|
| Neoplasms | 1 | 2014 | 15927 | 0.070 |
Why?
|
| Genetic Variation | 1 | 2015 | 2166 | 0.070 |
Why?
|
| Skin Neoplasms | 1 | 2004 | 4895 | 0.070 |
Why?
|
| Vincristine | 1 | 2011 | 1583 | 0.070 |
Why?
|
| Imatinib Mesylate | 1 | 2011 | 1691 | 0.070 |
Why?
|
| Cartilage | 1 | 2007 | 110 | 0.070 |
Why?
|
| Killer Cells, Natural | 1 | 2012 | 965 | 0.070 |
Why?
|
| Adipocytes, Brown | 1 | 2007 | 28 | 0.070 |
Why?
|
| Cells, Cultured | 1 | 2015 | 5694 | 0.070 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2011 | 894 | 0.070 |
Why?
|
| Microspheres | 1 | 2007 | 237 | 0.070 |
Why?
|
| Chondrogenesis | 1 | 2007 | 64 | 0.070 |
Why?
|
| Ki-67 Antigen | 2 | 2006 | 675 | 0.070 |
Why?
|
| Signal Transduction | 4 | 2006 | 12103 | 0.070 |
Why?
|
| Somatomedins | 1 | 2006 | 74 | 0.070 |
Why?
|
| Computational Biology | 1 | 2013 | 1291 | 0.070 |
Why?
|
| Neurites | 1 | 2006 | 70 | 0.070 |
Why?
|
| Chondrocytes | 1 | 2007 | 100 | 0.070 |
Why?
|
| Epigenesis, Genetic | 1 | 2014 | 1441 | 0.070 |
Why?
|
| Melanoma | 1 | 2004 | 5595 | 0.070 |
Why?
|
| Ossification, Heterotopic | 1 | 2007 | 70 | 0.070 |
Why?
|
| Vidarabine | 1 | 2011 | 1384 | 0.070 |
Why?
|
| Immunohistochemistry | 3 | 2014 | 7655 | 0.070 |
Why?
|
| Genome-Wide Association Study | 1 | 2015 | 2351 | 0.070 |
Why?
|
| Neoplasm Invasiveness | 1 | 2014 | 4048 | 0.070 |
Why?
|
| Genotype | 1 | 2014 | 4252 | 0.070 |
Why?
|
| DNA Methylation | 1 | 2016 | 2765 | 0.070 |
Why?
|
| Benzamides | 1 | 2011 | 1879 | 0.060 |
Why?
|
| Recurrence | 1 | 2014 | 4878 | 0.060 |
Why?
|
| Early Detection of Cancer | 1 | 2014 | 1340 | 0.060 |
Why?
|
| Transcription Factor AP-1 | 1 | 2006 | 249 | 0.060 |
Why?
|
| Osteogenesis | 1 | 2007 | 272 | 0.060 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2011 | 1347 | 0.060 |
Why?
|
| Infant, Newborn | 2 | 2015 | 8699 | 0.060 |
Why?
|
| Ganglia, Spinal | 1 | 2006 | 251 | 0.060 |
Why?
|
| Aged, 80 and over | 2 | 2015 | 30998 | 0.060 |
Why?
|
| Diagnosis, Differential | 1 | 2014 | 4831 | 0.060 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2012 | 1655 | 0.060 |
Why?
|
| Lymphatic Metastasis | 1 | 2014 | 4963 | 0.060 |
Why?
|
| Histone Acetyltransferases | 1 | 2006 | 433 | 0.060 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2014 | 4644 | 0.060 |
Why?
|
| Doxorubicin | 1 | 2011 | 3145 | 0.060 |
Why?
|
| Gene Expression Regulation | 2 | 2013 | 4130 | 0.060 |
Why?
|
| Cisplatin | 1 | 2011 | 2497 | 0.060 |
Why?
|
| Neoplasm Metastasis | 1 | 2014 | 5315 | 0.060 |
Why?
|
| Sialoglycoproteins | 1 | 2003 | 151 | 0.050 |
Why?
|
| Monocytes | 1 | 2007 | 790 | 0.050 |
Why?
|
| G2 Phase | 1 | 2004 | 218 | 0.050 |
Why?
|
| Fibroblast Growth Factors | 1 | 2004 | 257 | 0.050 |
Why?
|
| Time Factors | 4 | 2006 | 13006 | 0.050 |
Why?
|
| Survival Analysis | 1 | 2014 | 9292 | 0.050 |
Why?
|
| Oxygen | 1 | 2007 | 791 | 0.050 |
Why?
|
| Isoenzymes | 1 | 2005 | 648 | 0.050 |
Why?
|
| Nuclear Proteins | 1 | 2014 | 3438 | 0.050 |
Why?
|
| Trans-Activators | 2 | 2006 | 1624 | 0.050 |
Why?
|
| Piperazines | 1 | 2011 | 2145 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2004 | 537 | 0.050 |
Why?
|
| Brain | 1 | 2015 | 4208 | 0.050 |
Why?
|
| Disease-Free Survival | 1 | 2014 | 10265 | 0.050 |
Why?
|
| Cyclins | 1 | 2004 | 467 | 0.050 |
Why?
|
| Cyclin B1 | 1 | 2001 | 60 | 0.050 |
Why?
|
| Cyclin B | 1 | 2001 | 69 | 0.050 |
Why?
|
| Lac Operon | 1 | 2001 | 133 | 0.050 |
Why?
|
| Precipitin Tests | 1 | 2001 | 350 | 0.050 |
Why?
|
| Cytogenetics | 1 | 2001 | 152 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2003 | 382 | 0.050 |
Why?
|
| Neoplasm Staging | 2 | 2014 | 14012 | 0.050 |
Why?
|
| Chromosomes | 1 | 2001 | 325 | 0.050 |
Why?
|
| Transcription Factors | 1 | 2014 | 5438 | 0.040 |
Why?
|
| Animals | 8 | 2014 | 61956 | 0.040 |
Why?
|
| Muscle, Skeletal | 1 | 2007 | 1286 | 0.040 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2003 | 678 | 0.040 |
Why?
|
| Pregnancy | 1 | 2012 | 8130 | 0.040 |
Why?
|
| Cell Death | 1 | 2001 | 685 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2006 | 2069 | 0.040 |
Why?
|
| Pyrimidines | 1 | 2011 | 3669 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2011 | 5408 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2001 | 1050 | 0.040 |
Why?
|
| Cell Cycle | 1 | 2001 | 2137 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2009 | 5776 | 0.030 |
Why?
|
| DNA, Neoplasm | 1 | 2020 | 1958 | 0.030 |
Why?
|
| Mice, Inbred NOD | 2 | 2007 | 896 | 0.030 |
Why?
|
| Mice, Inbred CBA | 1 | 2014 | 79 | 0.030 |
Why?
|
| Mice | 7 | 2014 | 35600 | 0.030 |
Why?
|
| Cerebrum | 1 | 2014 | 40 | 0.030 |
Why?
|
| Hypertelorism | 1 | 2013 | 12 | 0.030 |
Why?
|
| Endoribonucleases | 1 | 2014 | 121 | 0.030 |
Why?
|
| Mice, SCID | 2 | 2007 | 1826 | 0.030 |
Why?
|
| Corpus Callosum | 1 | 2013 | 127 | 0.030 |
Why?
|
| Breast Neoplasms | 2 | 2014 | 16215 | 0.030 |
Why?
|
| Syndrome | 1 | 2015 | 1407 | 0.030 |
Why?
|
| Databases, Genetic | 1 | 2015 | 757 | 0.030 |
Why?
|
| Retrospective Studies | 1 | 2014 | 39890 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2015 | 1099 | 0.020 |
Why?
|
| Craniosynostoses | 1 | 2013 | 134 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 3 | 2007 | 7100 | 0.020 |
Why?
|
| RNA-Binding Proteins | 1 | 2014 | 1017 | 0.020 |
Why?
|
| 3T3 Cells | 1 | 2007 | 384 | 0.020 |
Why?
|
| Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Protein | 1 | 2006 | 25 | 0.020 |
Why?
|
| Hypoxanthine Phosphoribosyltransferase | 1 | 2006 | 45 | 0.020 |
Why?
|
| Tumor Necrosis Factor Receptor-Associated Peptides and Proteins | 1 | 2006 | 21 | 0.020 |
Why?
|
| Bone Morphogenetic Protein 2 | 1 | 2007 | 125 | 0.020 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2006 | 143 | 0.020 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2006 | 438 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2009 | 823 | 0.020 |
Why?
|
| Myeloid Cells | 1 | 2007 | 273 | 0.020 |
Why?
|
| Cell Hypoxia | 1 | 2007 | 353 | 0.020 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2007 | 247 | 0.020 |
Why?
|
| Stromal Cells | 1 | 2009 | 825 | 0.020 |
Why?
|
| Mice, Knockout | 2 | 2006 | 5728 | 0.020 |
Why?
|
| Coculture Techniques | 1 | 2006 | 628 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 2003 | 7914 | 0.020 |
Why?
|
| Young Adult | 2 | 2015 | 22251 | 0.020 |
Why?
|
| Phosphorylation | 2 | 2003 | 4942 | 0.010 |
Why?
|
| Nuclear Receptor Coactivator 3 | 1 | 2006 | 378 | 0.010 |
Why?
|
| Caspases | 1 | 2006 | 679 | 0.010 |
Why?
|
| Fibroblast Growth Factor 1 | 1 | 2003 | 18 | 0.010 |
Why?
|
| Proteoglycans | 1 | 2004 | 279 | 0.010 |
Why?
|
| Osteopontin | 1 | 2003 | 145 | 0.010 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2003 | 95 | 0.010 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2012 | 2453 | 0.010 |
Why?
|
| Adolescent | 2 | 2015 | 32767 | 0.010 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2003 | 185 | 0.010 |
Why?
|
| Disease Models, Animal | 2 | 2007 | 7381 | 0.010 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2001 | 65 | 0.010 |
Why?
|
| Transforming Growth Factor beta | 1 | 2007 | 1109 | 0.010 |
Why?
|
| Phosphoproteins | 1 | 2006 | 1138 | 0.010 |
Why?
|
| Growth Substances | 1 | 2001 | 326 | 0.010 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2006 | 1281 | 0.010 |
Why?
|
| Gene Silencing | 1 | 2003 | 827 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 2003 | 1553 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2003 | 1810 | 0.010 |
Why?
|
| Cell Line | 1 | 2007 | 5338 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2001 | 1525 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2006 | 3339 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2003 | 1580 | 0.010 |
Why?
|
| Alleles | 1 | 2003 | 2600 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2006 | 6177 | 0.010 |
Why?
|
| STAT3 Transcription Factor | 1 | 2001 | 1136 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2001 | 1875 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2001 | 5056 | 0.010 |
Why?
|
| Pancreatic Neoplasms | 1 | 2006 | 5257 | 0.010 |
Why?
|